NCT01279850 (RAINBOW-L) is a clinical trial of Pregabalin (Lyrica) capsule in Neuropathic Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Who is sponsoring NCT01279850?

NCT01279850 is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

What drugs are being tested in NCT01279850?

Interventions in NCT01279850: Pregabalin (Lyrica) capsule.

What condition does NCT01279850 study?

NCT01279850 studies Neuropathic Pain.

Is NCT01279850 still recruiting?

NCT01279850 is currently completed. Last updated 26 September 2023.

Are results published for NCT01279850?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-26 · How we verify

NCT01279850: RAINBOW-L

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SPECIAL INVESTIGATION OF LONG TERM USE OF LYRICA(REGULATORY POST MARKETING COMMITMENT PLAN)

Completed Results posted Last updated 26 September 2023

What this trial tests

trial testing Pregabalin (Lyrica) capsule in Neuropathic Pain in 891 participants. Completed in 1 July 2017.

Timeline

1 August 2011

Primary endpoint
1 July 2017

1 July 2017

Quick facts

Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	891
Start date	1 August 2011
Primary completion	1 July 2017
Estimated completion	1 July 2017

Drugs / interventions tested

Pregabalin (Lyrica) capsule

Conditions studied

Neuropathic Pain — all drugs for Neuropathic Pain →

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full company profile →

Who can join

0 Days and older, any sex, with Neuropathic Pain. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants With Adverse Drug Reaction
Time frame: From Week 1 to Week 104 at maximum
An adverse drug reaction (ADR) was any untoward medical occurrence attributed to LYRICA Capsules in a participant who received LYRICA Capsules. Relatedness to LYRICA Capsules was assessed by the physician.

Sponsor's own description

The objective of this investigation is to evaluate the safety and efficacy of long term use with Lyrica in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Lyrica will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pregabalin (Lyrica) capsule

Trials testing the same drug.

NCT01256593 — Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan) · completed

Other recruiting trials for Neuropathic Pain

Currently open trials in the same condition.

NCT07493213 — USG-Guided Shoulder Injections in Frozen Shoulder · NA · recruiting
NCT07493226 — Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis · NA · recruiting
NCT06398847 — Virtual Reality (VR) Self-Hypnosis Software · NA · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07436806 — SPS Block vs. Surgical Intercostal Block for Chronic Pain After Thoracoscopic Surgery · NA · recruiting

Other Pfizer's Upjohn has merged with Mylan to form Viatris Inc. trials

Trials by the same sponsor.

NCT04391868 — A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form · Phase 1 · withdrawn
NCT04176367 — An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactu · Phase 1 · completed
NCT03768726 — Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents · Phase 3 · terminated
NCT03711708 — Relative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets · Phase 4 · completed
NCT03342690 — Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01279850 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01279850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing